<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2212">
  <stage>Registered</stage>
  <submitdate>16/12/2008</submitdate>
  <approvaldate>16/12/2008</approvaldate>
  <nctid>NCT00809575</nctid>
  <trial_identification>
    <studytitle>Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes</studytitle>
    <scientifictitle>Prognostic Significance and Longitudinal Assessment of Patient-reported Quality of Life and Symptoms in Myelodysplastic Syndromes. A Large-scale International, Observational Study: PROMYS Study</scientifictitle>
    <utrn />
    <trialacronym>PROMYS</trialacronym>
    <secondaryid>GIMEMA-QOL-MDS-0108</secondaryid>
    <secondaryid>QOL-MDS0108</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Adult</healthcondition>
    <healthcondition>Myelodysplastic Syndromes</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - questionnaire administration
Other interventions - fatigue assessment and management
Other interventions - observation
Other interventions - quality-of-life assessment

Other interventions: questionnaire administration


Other interventions: fatigue assessment and management


Other interventions: observation


Other interventions: quality-of-life assessment


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To investigate the prognostic value of baseline patients' reported fatigue for overall survival in newly diagnosed myelodysplastic syndrome (MDS) patients.</outcome>
      <timepoint>After 5 years from study entry.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To investigate the prognostic value of changes overtime of QoL and symptoms for clinical outcomes. - i.e. overall survival, AML transformation, toxicity and response to therapy.</outcome>
      <timepoint>After 5 years from study entry.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To describe prospectively short and long-term symptom burden and QoL outcomes by risk group and by type of therapy.</outcome>
      <timepoint>After 5 years from study entry.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the QoL of lower risk patients who maintain stable disease versus those who have progressed to AML or higher-risk score categories.</outcome>
      <timepoint>After 5 years from study entry.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the QoL and symptoms baseline reference data to be used as benchmarks for comparisons in clinical trials.</outcome>
      <timepoint>After 5 years from study entry.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To establish international QoL and symptoms baseline reference data to be used as benchmarks for comparisons in clinical trials.</outcome>
      <timepoint>After 5 years from study entry.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the impact of transfusion dependency at baseline and over time on survival and QoL outcomes.</outcome>
      <timepoint>After 5 years from study entry.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To devise a prognostic patient-based index.</outcome>
      <timepoint>After 5 years from study entry.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate accuracy of clinical prediction of survival.</outcome>
      <timepoint>After 5 years from study entry.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess patients' preferences for involvement in treatment decision-making across different risk group and examine relationships between preferences and patient characteristics.</outcome>
      <timepoint>After 5 years from study entry.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria

          -  Patients with newly diagnosed myelodysplastic syndrome (MDS) according to WHO
             classification with any known IPSS risk score category. The initial diagnosis of MDS
             is acceptable within 6 months before date of registration.

          -  Having a full baseline QoL Evaluation completed (i.e. EORTC QLQ-C30; EQ5DFACIT-Fatigue
             and Control Preference Scale).

          -  Adult patients (= 18 years old).

          -  Written informed consent provided.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria

          -  Patients who have received prior treatment other than platelets or RBC transfusions,
             iron chelation, antibiotic/virostatic drugs, vitamins;

          -  Patients with therapy related MDS.

          -  Having any kind of psychiatric disorder or major cognitive dysfunction.

          -  Not able to read and understand local language.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1070</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/05/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <postcode> - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Innsbruck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brugge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>China</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Kunming</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Cosenza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Foggia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bari</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Brescia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Cagliari</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Catania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Catanzaro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Latina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lecce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Livorno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Meldola</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Modena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Napoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Novara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Orbassano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Palermo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pavia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pescara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Prato</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ravenna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rimini</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rovigo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Sassari</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bradford</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Gruppo Italiano Malattie EMatologiche dell'Adulto</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Gathering information about quality of life, fatigue, and other symptoms from
      patients with myelodysplastic syndromes may help doctors learn more about the disease and may
      help plan treatment.

      PURPOSE: This clinical trial is studying quality of life and symptoms in patients with newly
      diagnosed myelodysplastic syndromes.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00809575</trialwebsite>
    <publication>Efficace F, Gaidano G, Sprangers M, Cottone F, Breccia M, Voso MT, Caocci G, Stauder R, Di Tucci AA, Sanpaolo G, Selleslag D, Angelucci E, Platzbecker U, Mandelli F. Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes. Ann Oncol. 2014 Feb;25(2):447-54. doi: 10.1093/annonc/mdt557.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Fabio Efficace, PhD</name>
      <address>Gruppo Italiano Malattie EMatologiche dell'Adulto</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Francesca Tartaglia</name>
      <address />
      <phone />
      <fax />
      <email>promys@gimema.it</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>